Kendall Griffith, MD
Interventional Cardiology · Statesboro, GANPI 1710968060
Payments from drug & device makers
Across 339 payments — averaging $62.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Abbott$2K
- Cardiovascular Systems Inc.$1K
- Boston Scientific$878
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$763
- AstraZeneca$720
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$4,55021%
- Travel & lodging$8,57340%
- Food & beverage$8,17738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $12,097 |
| Abbott | 21 | $1,504 |
| Cardiovascular Systems Inc. | 11 | $1,314 |
| Boston Scientific | 36 | $878 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $763 |
| AstraZeneca | 29 | $720 |
| Novartis | 29 | $539 |
| Merck | 24 | $492 |
| Abiomed | 5 | $419 |
| Shockwave Medical, Inc | 14 | $353 |
| Atricure, Inc. | 5 | $341 |
| Boehringer Ingelheim | 16 | $289 |
| Cvrx, Inc. | 11 | $265 |
| Philips North America LLC | 13 | $265 |
| Lexicon Pharmaceuticals, Inc. | 16 | $212 |
| Inari Medical, Inc. | 2 | $132 |
| Baxter Healthcare | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Johnson & Johnson | 4 | $65 |
| Vital Connect, Inc | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $53 |
| Pfizer | 3 | $47 |
| Amgen | 3 | $41 |
| Exact Sciences | 2 | $35 |
| Novo Nordisk | 2 | $34 |
| Bayer | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Acist Medical Systems, Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Stryker | 1 | $23 |
| Medicomp Inc | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Cleerly, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLIA MRI QUAD CRT-D SURESCAN$2,240
- VenaSeal$1,903
- Micra$1,258
- Coronary Orbital Atherectomy System$1,158
- Peripheral Orbital Atherectomy System$1,158
- SUPERA$747
- Impella$266
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$252
- LifeVest$235
- AVEIR$190
- SYMPLICITY G3$167
- FARXIGA$125
- FLOWTRIEVER CATHETER, S$118
- CT THROMBECTOMY SYSTEM KIT$118
- ASSURITY$101
How this compares
$21,300 in reported general payments places this provider in the 65th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 221 | $200,328 |
| EliquisApixaban | 198 | $137,152 |
| FarxigaDapagliflozin Propanediol | 58 | $48,276 |
| BrilintaTicagrelor | 75 | $43,965 |
| XareltoRivaroxaban | 33 | $27,879 |
| JardianceEmpagliflozin | 13 | $14,481 |
| Repatha SureclickEvolocumab | 19 | $10,496 |
| CorlanorIvabradine Hcl | 18 | $10,232 |
| Ranolazine ErRanolazine | 110 | $6,868 |
| Nifedipine ErNifedipine | 184 | $3,005 |
| Metoprolol Succinate | 299 | $2,220 |
| Flecainide Acetate | 75 | $1,470 |
| Amiodarone Hcl | 82 | $1,442 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 112 | $1,233 |
| Carvedilol | 229 | $1,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $539 | $200,328221 claims |
| PfizerEliquis | $47 | $137,152198 claims |
| AstraZenecaFarxiga, Brilinta | $720 | $92,240133 claims |
| Johnson & JohnsonXarelto | $65 | $27,87933 claims |
| Boehringer IngelheimJardiance | $289 | $14,48113 claims |
| AmgenCorlanor | $41 | $10,23218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Statesboro
- Richard PetrellaStatesboro$44K
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.